Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Victor Adepoju | Global Health | Excellence in Research

Posted on by Phenomenological Research Awards

Dr. Victor Adepoju | Global Health | Excellence in Research

Director, Infectious diseases and Research at Jhpiego, Nigeria.

Dr. Victor Adepoju is a distinguished public health physician, researcher, and strategic information expert with over 14 years of experience managing large-scale global health programs across various income settings. As a Portfolio Director at Jhpiego, an affiliate of Johns Hopkins University, he leads multi-million-dollar projects in infectious diseases, maternal health, and immunization. With expertise in TB, HIV, viral hepatitis, and health systems strengthening, he has over 70 peer-reviewed publications and has contributed to WHO guidelines. Fluent in English and Yoruba, he is a global health leader driving universal health coverage and healthcare innovation.

Professional Profile:

Google Scholar

Education & Experience 🎓💼

  • MBChB (Bachelor of Medicine & Surgery) – Obafemi Awolowo University 🏥
  • MSc (International Management of Health Systems) – University of Liverpool 🌍
  • Master Certificate in Healthcare Leadership – Cornell University 🎯
  • PhD (Public Health) – Crown International University 🏆
  • Portfolio Director, Jhpiego (Johns Hopkins University Affiliate) (2021–Present) 🌍
  • Over 14 years in global health, working with USAID, Global Fund, GAVI, and UNITAID 💡

Professional Development 📈🩺

Dr. Adepoju is a seasoned expert in global health implementation, policy, and research. He has designed and led health interventions for TB, HIV, maternal and child health, and neglected tropical diseases, securing over $100 million in funding. His work in operational research, health systems strengthening, and digital health innovations has shaped policies globally. With experience in capacity building, health financing, and universal health coverage, he has collaborated with Ministries of Health, civil society, and donors. A thought leader in market shaping, he drives equitable access to healthcare solutions for vulnerable populations worldwide.

Research Focus 🔬📚

Dr. Adepoju’s research spans infectious diseases (HIV, TB, viral hepatitis, COVID-19, and mpox), neglected tropical diseases, and maternal, newborn, and child health (MNCH). His expertise extends to universal health coverage, health systems strengthening, and innovative diagnostics. He is a leader in market shaping, improving access to essential medicines and vaccines in low- and middle-income countries (LMICs). His work also includes health financing, strategic information, and public-private partnerships. His contributions to implementation science have shaped WHO policies and national health guidelines across multiple regions.

Awards & Honors 🏅🎖

  • An Excellence in Global Health Leadership Award 🌍🏆
  • USAID/Global Fund Project Recognition Award 🏥💡
  • Jhpiego Outstanding Leadership Award 🏅
  • Best Public Health Research Paper Award 📖
  • UNITAID Health Innovation Award 💉
  • Certificate of Excellence in Health Systems Strengthening 🏆
  • Recognition for Policy Contribution to WHO Guidelines 📜

Publication Top Notes

📄 Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 402 (10397), 203-234 📅 2023 🔍 Cited by: 1972

📄 Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990–2021 – The Lancet 403 (10440), 2133-2161 📅 2024 🔍 Cited by: 566

📄 Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2100-2132 📅 2024 🔍 Cited by: 530

📄 Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic – The Lancet 403 (10440), 1989-2056 📅 2024 🔍 Cited by: 321

📄 The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis – The Lancet Global Health 12 (2), e201-e216 📅 2024 🔍 Cited by: 112

📄 Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2057-2099 📅 2024 🔍 Cited by: 97

📄 Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 – The Lancet Infectious Diseases 24 (9), 974-1002 📅 2024 🔍 Cited by: 60

📄 Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the Global Burden of Disease Study 2019 – EClinicalMedicine 64 📅 2023 🔍 Cited by: 54

📄 Prevalence of rifampicin-resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos, Nigeria – African Health Sciences 18 (3), 472-478 📅 2018 🔍 Cited by: 48

📄 Childhood tuberculosis in Nigeria: disease presentation and treatment outcomes – Health Services Insights 11, 1178632918757490 📅 2018 🔍 Cited by: 40

Nazanin mahinparvar | Medicine | Best Researcher Award

Posted on by Phenomenological Research Awards

Nazanin mahinparvar | Medicine | Best Researcher Award

Postdoc at Stanford university, United States.

Dr. Nazanin Mahinparvar is a postdoctoral scholar at Stanford University, focusing on bioengineering and pain management. She brings a blend of medical and research expertise to her work, aiming to develop innovative gene therapies that offer non-addictive, effective treatments for chronic pain. Her research in synthetic biology, combined with her clinical background as an emergency medicine physician, underscores her commitment to translating laboratory discoveries into practical healthcare solutions. Throughout her career, she has received numerous accolades for her dedication to patient care and research excellence, including the Best Physician Award during the COVID-19 pandemic. Her approach to research is driven by a patient-centered perspective, making her work both scientifically rigorous and highly relevant to addressing current health challenges. Dr. Mahinparvar’s focus on developing HSV-based biotechnologies has the potential to reshape pain management therapies, positioning her as a significant contributor to advancements in medical science.

Profile👤

Scopus

Education 🎓

Dr. Nazanin Mahinparvar’s educational journey is marked by excellence and a clear dedication to advancing medical knowledge. She began her studies in Biology at SAMPAD in Iran, followed by an MD at Isfahan Medical University, where she was recognized with high honors. Her medical education included an emphasis on pain management, an area she explored further during her mandatory medical service program. Her commitment to lifelong learning and research brought her to Stanford University for a prestigious postdoctoral position in bioengineering. Dr. Mahinparvar’s educational background integrates both foundational medical training and specialized knowledge in synthetic biology and gene therapy. Her academic journey has been marked by a strong interdisciplinary focus, with formal training that spans basic sciences, clinical practice, and cutting-edge bioengineering. This diverse educational foundation provides her with a unique perspective, enabling her to bridge the gap between laboratory research and patient-centered clinical applications.

Experience💼

Dr. Nazanin Mahinparvar has extensive experience in both clinical and research settings, blending hands-on patient care with innovative scientific research. Her early career as a physician involved managing healthcare in underserved areas, where she was honored with the Best Doctor Award for her exceptional patient care. Following this, she served as an emergency medicine physician, honing her ability to operate under pressure. During her postdoctoral work at Stanford, she focused on developing non-toxic HSV-based therapies for chronic pain and neurological disorders. Her clinical experience in pain management, coupled with her research in gene therapy and synthetic biology, has positioned her as a leader in innovative medical research. Dr. Mahinparvar’s experience is a blend of practical and scientific expertise, which she continually refines through collaboration with top scientists and participation in clinical trials. Her background uniquely equips her to drive impactful advancements in pain management and gene-based therapies.

Research Interests 🔬

Dr. Mahinparvar’s research interests focus on engineering advanced, safe, and efficient gene therapies for chronic pain and neurological disorders. She specializes in developing non-addictive pain management treatments using synthetic biology and gene engineering, with a particular interest in non-toxic HSV-based technologies. Dr. Mahinparvar’s work aims to address global health challenges by providing affordable, accessible solutions for conditions that currently lack effective, low-risk treatments. At Stanford’s Wu Tsai Neurosciences Institute, her research delves into combining gene therapy with bioengineering to create precise, targeted interventions. Her early research on selenium’s effects on respiratory functions in ICU patients sparked her interest in translational medicine, which she has expanded to chronic pain and neuro-oncology applications. Dr. Mahinparvar’s research is ultimately driven by her commitment to improving patient outcomes and advancing the field of pain management through innovative, cross-disciplinary approaches that bridge the laboratory and the clinic.

Awards and Honors 🏆

Throughout her career, Dr. Mahinparvar has earned multiple awards recognizing her excellence in both research and clinical practice. In 2021, she received the Best Physician Award for her dedication to patient care during the COVID-19 pandemic, reflecting her commitment to providing quality healthcare under challenging conditions. She was also honored with the Foundation of Future Medical Research Fellowship at the Kheradmand Institute, which brought her to Stanford for advanced research in head and neck surgery and gene therapy. Other accolades include her high-honors MD dissertation award and the Best Student Award from Iran’s SAMPAD organization for exceptional talent. These recognitions highlight Dr. Mahinparvar’s leadership, resilience, and contribution to medicine. Her awards underscore her determination to push the boundaries of traditional pain management, making her a strong candidate for future honors in the fields of bioengineering and clinical research.

Conclusion 🔚 

Dr. Mahinparvar’s academic and clinical achievements, including her innovative work in chronic pain management, place her among the most promising candidates for the Best Researcher Award. Her interdisciplinary research, combined with her commitment to patient care and clinical applications, demonstrates her potential to make lasting contributions to medical science and public health. This award would provide well-deserved recognition and support to advance her impactful research on a global scale.

Publications Top Notes 📚

Title: Oxytocin Receptors on Calvarial Periosteal Innervation: Therapeutic Target for Post-Traumatic Headache?
Authors: Bharadwaj, V.N., Klukinov, M., Cowan, R.P., Mahinparvar, N., Clark, D.J., Yeomans, D.C.
Year: 2024
Journal: Pharmaceutics, 16(6), 760
Citation Count: 0

Title: Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status
Authors: Hesari, A., Azizian, M., Sheikhi, A., Nesaei, A., Sanaei, S., Mahinparvar, N., Derakhshani, M., Hedayt, P., Ghasemi, F., Mirzaei, H.
Year: 2019
Journal: International Journal of Cancer, 144(6), pp. 1215–1226
Citation Count: 103

Title: Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis
Authors: Etemadifar, M., Ghourchian, S., Mahinparvar, N., Sanaei, S., Akbari, M.
Year: 2019
Journal: Acta Medica Iranica, 57(8), pp. 484–491
Citation Count: 2

Title: Comparison of the efficacy of midazolam and dexmedetomidine in quality of sedation in mechanically-ventilated patients admitted to intensive care unit
Authors: Kashefi, P., Mahinparvar, N., Khalifsoltani-Khajooie, M., Mansouri, P., Sanaei, S.
Year: 2018
Journal: Journal of Isfahan Medical School, 35(460), pp. 1799–1805
Citation Count: 1

Title: The effect of selenium on maximum inspiratory pressure in patients under mechanical ventilation in intensive care units
Authors: Alikiaii, B., Mahinparvar, N.
Year: 2017
Journal: Journal of Isfahan Medical School, 35(423), pp. 291–296
Citation Count: 1